Drugs / Nebivolol
Nebivolol
also known as
NEB · Nebilet · Bystolic · Bystolic (nebivolol) · Hypoloc · Narbivolol · Nebivolol component of byvalson · Nebivolol hcl · +6 more
Other / unclassified targets ADRB1, ADRB2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BYSTOLIC | — | 2010-02-19 | fda.gov ↗ |
| Approved | US (FDA) | BYSTOLIC | — | 2007-12-17 | fda.gov ↗ |
Trials 66 · started per year
today
US approved 2007
4
3
1
3
1
1
2
7
6
4
6
2
1
2
2
3
2
1
4
6
4
1
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01358409 | Apr 2011 → Feb 2013 | triglyceride deposit cardiomyovasculopathy | Lidia Szczepaniak | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06248099 | Jul → Aug 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04888728 | Jun → Jul 2021 | idiopathic pulmonary fibrosis | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT00158093 | Jun → Jul 2003 | essential hypertension | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07233499 | Jan 2025 → Feb 2027 expected | HER2 positive breast carcinoma | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT04910100 | Apr 2021 → Mar 2022 | ocular hypertension, open-angle glaucoma | Betaliq, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03655964 | Aug 2018 → Aug 2019 | ischemic stroke | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 2 | NCT01679652 | Aug 2012 → Sep 2013 | essential hypertension | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 2 | NCT00200421 | May 2002 → Aug 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06201611 | Nov 2024 → Dec 2025 overdue | diabetic polyneuropathy | St. John's Research Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06424834 | Oct 2024 → Dec 2026 expected | coronary artery intramyocardial course, coronary microvascular disorder, coronary vasospasm, intermediate coronary syndrome | Stanford University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00829296 | Jan 2009 → Apr 2012 | hypertensive disorder, type 2 diabetes mellitus | University of Chicago | Completed | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT06755801 | Apr 2025 → Mar 2026 overdue | coronary microvascular disorder, nonobstructive coronary artery disease | Spanish Society of Cardiology | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04631536 | Jan 2021 → Mar 2022 | COVID-19 | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05728632 | Jan 2019 → Feb 2023 | breast cancer, chemotherapy-induced toxicity, diffuse large B-cell lymphoma, left ventricular failure | Giulio Stefanini | Unknown | No outcome recorded |
| Phase 3 | NCT01648634 | Feb 2012 → Jul 2021 | Duchenne muscular dystrophy, cardiomyopathy, heart failure | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01508026 | Jan 2012 → Mar 2013 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01415505 | Aug 2011 → Jan 2013 | essential hypertension | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01499134 | Aug 2011 → Jun 2014 | hypertensive disorder, peripheral arterial disease | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 3 | NCT00683124 | Jul 2008 → Jul 2013 | Marfan syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00547300 | Oct 2007 → Jan 2008 | hypertensive disorder | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00142584 | Aug 2005 → Mar 2008 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00942487 | Apr 2005 → Dec 2008 | essential hypertension | Berlin-Chemie Menarini | Completed | No outcome recorded |
| Phase 3 | NCT00145210 | Apr 2005 → Sep 2007 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00200434 | Oct 2002 → Oct 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00200499 | Mar 2002 → Sep 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00145236 | Nov 2001 → Aug 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00200473 | Sep 2001 → Mar 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00200460 | Sep 2001 → Mar 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 427 trials | ||||||
| Phase 4 | NCT04432610 | Jan → Dec 2030 | — | Clinical Hospital Center Zemun | Withdrawn | No outcome recorded |
| Phase 4 | NCT06249802 | Jan 2025 → Jan 2029 expected | brain aneurysm | Jagiellonian University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06035978 | Mar 2024 → Apr 2026 | symptomatic heart failure | University Hospital Ostrava | Unknown | No outcome recorded |
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04769362 | May 2021 → Jan 2026 overdue | myocardial infarction | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT03778554 | Dec 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Bispebjerg Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03596385 | Oct 2018 → Jan 2025 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT03245996 | Jun 2015 → Sep 2016 | — | Tartu University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02710071 | Jan 2015 → Apr 2016 | essential hypertension | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02053246 | Jan 2014 → Mar 2021 | diastolic heart failure, pulmonary hypertension | University of Florida | Terminated | No outcome recorded |
| Phase 4 | NCT01665508 | Apr 2013 → May 2015 | coronary microvascular disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01771406 | Feb 2013 → Feb 2016 | hypertensive disorder, obstructive sleep apnea syndrome | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| Phase 4 | NCT01605370 | Jun 2012 → Mar 2013 | hypertensive disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT01961323 | Mar 2012 → Mar 2016 | hypertensive disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT01595516 | Feb 2012 → Oct 2017 | hypertensive disorder | University of Colorado, Boulder | Completed | No outcome recorded |
| Phase 4 | NCT01415531 | Aug 2011 → Mar 2012 | essential hypertension | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00992056 | Dec 2010 → Feb 2012 | hypertensive disorder | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT01218100 | Oct 2010 → May 2011 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01206439 | Sep 2010 → Aug 2012 | hypertensive disorder | Jack Rubinstein | Terminated | No outcome recorded |
| Phase 4 | NCT01202175 | Jul 2010 → Jun 2012 | hypertensive disorder | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01057251 | Mar → Dec 2010 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00999102 | Oct 2009 → Jan 2011 | hypertensive disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT00893984 | May 2009 → Jun 2012 | coronary artery disorder | Minneapolis Heart Institute Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT00744237 | Aug 2008 → Jul 2010 | hypertensive disorder, type 2 diabetes mellitus | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01248338 | Mar 2006 → Dec 2008 | hypertensive disorder | Berlin-Chemie Menarini | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07123506 | Sep 2025 → Nov 2028 expected | atrial fibrillation, atrial flutter, atrial septal defect | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT05328310 | Jan 2019 → Dec 2022 | hypertensive disorder | Korea University Anam Hospital | Unknown | No outcome recorded |
| — | NCT02619526 | Dec 2016 → Jul 2018 | heart failure | Dong-A University | Unknown | No outcome recorded |
| — | NCT01044693 | Jan 2010 → Jul 2014 | hypertensive disorder, pure autonomic failure | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01051947 | Dec 2009 → May 2010 | — | Creighton University | Withdrawn | No outcome recorded |
| — | NCT01056718 | Nov 2009 → Nov 2013 | hypertensive disorder | Mercy Research | Completed | No outcome recorded |
| — | NCT00995072 | Oct 2009 → Apr 2013 | hypertensive disorder, sexual disorder | East Coast Institute for Research | Completed | No outcome recorded |
| — | NCT00849810 | Jan 2009 → Nov 2010 | hypertensive disorder | University of Mississippi Medical Center | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 45 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02467400 Comparator | Jul 2015 → Oct 2017 | postmenopausal osteoporosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04130438 Comparator | Oct 2020 → Mar 2022 | coronary artery intramyocardial course | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT01522950 Comparator | May 2010 → Oct 2016 | hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01939990 Comparator | Jan 2012 → Mar 2013 | hypertensive disorder | University of Chicago | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05170061 Comparator | Feb 2013 → Sep 2014 | hypertensive disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT00648895 Comparator | Nov 2007 → Jul 2009 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT07397481 Comparator | Mar 2024 → Mar 2025 | cirrhosis of liver, hypertensive disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT06104423 Comparator | Oct 2023 → Feb 2024 | hypertensive disorder | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT05513937 Comparator | May → Nov 2022 | hypertensive disorder | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT04845061 Comparator | Oct → Dec 2021 | chronic obstructive pulmonary disease | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT05257148 Comparator | May → Dec 2021 | hypertensive disorder | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03930433 Comparator | Jan 2018 → Mar 2019 | coronary vasospasm | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03180593 Comparator | Feb 2017 → Jan 2018 | heart disorder, hypertensive disorder | Trinity Hypertension & Metabolic Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01885988 Comparator | Mar 2013 → Mar 2014 | erectile dysfunction | Martin M. Miner, MD | Unknown | No outcome recorded |
| Phase 4 | NCT01395329 Comparator | May 2011 → Nov 2016 | hypertensive disorder | University of Colorado, Boulder | Completed | No outcome recorded |
| Phase 4 | NCT02057328 Comparator | Dec 2010 → Jan 2015 | hypertensive disorder | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 4 | NCT03635125 Comparator | Aug 2010 → May 2011 | — | Trinity Hypertension & Metabolic Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01501929 Comparator | Aug 2010 → Dec 2015 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01157234 Comparator | Jul 2010 → Jul 2014 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT01230892 Comparator | Feb 2010 → Sep 2013 | atherosclerosis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01920282 Comparator | Jan 2010 → Aug 2012 | hypertensive disorder | Virginia Polytechnic Institute and State University | Completed | No outcome recorded |
| Phase 4 | NCT01049009 Comparator | Dec 2009 → Jun 2012 | hypertensive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01041287 Comparator | Dec 2009 → Dec 2013 | hypertensive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01502787 Comparator | Apr 2009 → Jun 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00785512 Comparator | Nov 2008 → Aug 2009 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00775671 Comparator | Oct 2008 → Jun 2011 | metabolic syndrome X | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00770861 Comparator | Sep 2008 → Nov 2009 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00734630 Comparator | Aug 2008 → Mar 2010 | essential hypertension | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00673790 Comparator | May 2008 → Jul 2010 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00673075 Comparator | May 2008 → Sep 2009 | coronary artery disorder, hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00517725 Comparator | Jul 2007 → May 2010 | congestive heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 4 | NCT00924833 Comparator | May → Nov 2006 | altitude sickness, heart failure | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT01996085 Comparator | Jan 2013 → Jun 2016 | hypertensive disorder | Military Institute od Medicine National Research Institute | Completed | No outcome recorded |
| — | NCT01441570 Comparator | Feb 2012 → Jul 2013 | hypertensive disorder | Brigham and Women's Hospital | Terminated | No outcome recorded |
| — | NCT01076140 Comparator | Feb 2010 → Jan 2011 | hypertensive disorder | University of Mississippi Medical Center | Withdrawn | No outcome recorded |
| — | NCT00999752 Comparator | Oct 2009 → Feb 2010 | hypertensive disorder | InVasc Therapeutics, Inc. | Completed | No outcome recorded |
| — | NCT00878384 Comparator | Apr 2009 → Jun 2012 | atrial fibrillation, heart failure | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00125853 Comparator | Jul 2006 → Jan 2009 | hypertensive disorder | Imperial College London | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 116 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nebivolol | “Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol...” PMID 39645270 ↗ Aug 2024110“Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration” NCT00942487 ↗ “The beta-blockers used in this study are extended-release beta-blockers, specifically bisoprolol or nebivolol.” NCT07123506 ↗ “betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol” NCT03596385 ↗ “Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension.” NCT01049009 ↗ “Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol” NCT04575675 ↗ “Study group: Nebivolol • Patients will start with a dose of 5 mg every 24 hours.” NCT06755801 ↗ “Beta blocker: carvedilol, metroprolol, bisoprolol or nebivolol” NCT07513883 ↗ “Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks” NCT03180593 ↗ “nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop” NCT02200822 ↗ “Nebivolol 1.25-10mg o.d.” NCT00878384 ↗ “Nebivolol 10mg/d” NCT02817360 ↗ “nebivolol” NCT04767061 ↗ “nebivolol” NCT04757584 ↗ |
| Known as | Bystolic | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | Bystolic (nebivolol) | “Bystolic® (nebivolol)” NCT00785512 ↗ |
| Known as | Hypoloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | Narbivolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | NEB | “This is a Phase IV, interventional, multicenter, open-label, multinational study with 2 study periods (a Run-in period of 4 weeks and an Assessment period of 12 weeks) to...” NCT06104423 ↗4“The goal of this study was to assess whether nebivolol (NEB), a vasodilatory β(1)-selective blocker, is a safe and efficacious monotherapy for individuals with systolic stage...” PMID 23332366 ↗ Jan 2013 “Nebivolol (NEB) in contrast to atenolol (ATE) may have a beneficial effect on endothelial function and may be more effective than ATE in preventing CVD.” PMID 29184167 ↗ Nov 2017 “We compared an angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB) and the combination of NEB/VAL” PMID 26116459 ↗ Mar 2015 “Nebivolol (NEB)” NCT00142584 ↗ |
| Known as | Nebilet | “Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ |
| Known as | Nebivolol component of byvalson | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | Nebivolol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | NEBIVOLOL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | Nebivolol hydrochloride component of byvalson | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | Nebivolol is bystolic | “Nebivolol is bystolic” NCT00849810 ↗ |
| Known as | R-067555 | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | R-65824 | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Known as | RO67555 | ChEMBL registry synonym — accepted as the source's own label CHEMBL434394 ↗ |
| Action | Inhibit | “The third-generation beta-adrenergic blocker nebivolol retains the beta-adrenergic blocker effects” PMID 19430350 ↗ Apr 20092“Beta-2 adrenergic receptor antagonist” CHEMBL434394 ↗ “Beta-1 adrenergic receptor antagonist” CHEMBL434394 ↗ |
| Modality | Other / unclassified | “The third generation beta-blocker, nebivolol, has vasodilating properties in addition to beta-adrenergic blockade.” NCT01499134 ↗ |
| Route | Oral | “nebivolol administered orally once daily” NCT00200499 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL434394 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL434394 ↗ |